Cyteir Therapeutics, Inc.
CYT
Price:
$3.02
Market Cap:
$108.71M
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.[Read more]
Industry
Biotechnology
IPO Date
2021-06-18
Stock Exchange
NASDAQ
Ticker
CYT
The ROE as of September 2024 (TTM) for Cyteir Therapeutics, Inc. (CYT) is -23.13%
According to Cyteir Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -23.13%. This represents a change of 302.00% compared to the average of -5.75% of the last 4 quarters.
Cyteir Therapeutics, Inc. (CYT) Historical ROE (quarterly & annually)
How has CYT ROE performed in the past?
The mean historical ROE of Cyteir Therapeutics, Inc. over the last ten years is 11.04%. The current -23.13% ROE has changed -309.50% with respect to the historical average. Over the past ten years (40 quarters), CYT's ROE was at its highest in in the March 2021 quarter at 13.42%. The ROE was at its lowest in in the March 2023 quarter at -8.56%.
Average
11.04%
Median
10.56%
Minimum
-30.05%
Maximum
53.09%
Cyteir Therapeutics, Inc. (CYT) ROE by Quarter and Year
Discovering the peaks and valleys of Cyteir Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 35.12%
Maximum Annual ROE = 53.09%
Minimum Annual Increase = -151.29%
Minimum Annual ROE = -30.05%
| Year | ROE | Change |
|---|---|---|
| 2022 | -30.05% | 35.12% |
| 2021 | -22.24% | -151.29% |
| 2020 | 43.35% | -18.34% |
Cyteir Therapeutics, Inc. (CYT) Average ROE
How has CYT ROE performed in the past?
The current ROE of Cyteir Therapeutics, Inc. (CYT) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-2.98%
5-year avg
11.04%
10-year avg
11.04%
Cyteir Therapeutics, Inc. (CYT) ROE vs. Peers
How is CYT’s ROE compared to its peers?
Cyteir Therapeutics, Inc.’s ROE is greater than Nuvation Bio Inc. (-98.79%), greater than Magenta Therapeutics, Inc. (-61.71%), greater than Neoleukin Therapeutics, Inc. (-47.64%), greater than Graphite Bio, Inc. (-57.96%), less than Foghorn Therapeutics Inc. (140.34%), greater than C4 Therapeutics, Inc. (-44.60%), greater than Prelude Therapeutics Incorporated (-59.82%), greater than Rezolute, Inc. (-60.90%), greater than Molecular Partners AG (-33.08%), greater than MediciNova, Inc. (-13.37%), greater than Anebulo Pharmaceuticals, Inc. (-122.97%), less than Champions Oncology, Inc. (323.52%), greater than Eliem Therapeutics, Inc. (-47.03%), greater than HCW Biologics Inc. (-385.90%), greater than Monte Rosa Therapeutics, Inc. (-70.40%), greater than Nkarta, Inc. (-28.83%), greater than Lyell Immunopharma, Inc. (-33.35%), greater than Generation Bio Co. (-92.86%), greater than Sana Biotechnology, Inc. (-71.60%),
| Company | ROE | Market cap |
|---|---|---|
| -98.79% | $764.59M | |
| -61.71% | $42.44M | |
| -47.64% | $8.20M | |
| -57.96% | $185.19M | |
| 140.34% | $517.32M | |
| -44.60% | $437.87M | |
| -59.82% | $143.06M | |
| -60.90% | $285.64M | |
| -33.08% | $172.94M | |
| -13.37% | $89.75M | |
| -122.97% | $54.20M | |
| 323.52% | $69.76M | |
| -47.03% | $551.23M | |
| -385.90% | $22.69M | |
| -70.40% | $359.95M | |
| -28.83% | $396.54M | |
| -33.35% | $311.04M | |
| -92.86% | $165.18M | |
| -71.60% | $987.75M |
Build a custom stock screener for Cyteir Therapeutics, Inc. (CYT) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cyteir Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Cyteir Therapeutics, Inc. (CYT) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Cyteir Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Cyteir Therapeutics, Inc.'s ROE?
How is the ROE calculated for Cyteir Therapeutics, Inc. (CYT)?
What is the highest ROE for Cyteir Therapeutics, Inc. (CYT)?
What is the 3-year average ROE for Cyteir Therapeutics, Inc. (CYT)?
What is the 5-year average ROE for Cyteir Therapeutics, Inc. (CYT)?
How does the current ROE for Cyteir Therapeutics, Inc. (CYT) compare to its historical average?